HAMPTON, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”...
-Barzolvolimab met primary endpoint with clinically meaningful and statistically significant decreases in...
- Response observed as early as week 1 and durable for up to 16 weeks -- Data support important role for mast...
- Phase 2 CSU enrollment complete; topline data by YE 2023 -- Phase 1b PN data accepted at World Congress on...
HAMPTON, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.